Single Domain Biotherapeutics

Single Domain Biotherapeutics

Optimising next generation T-cell re-directing immunotherapy

A role for VHH single
domain antibodies

Welcome to

Isogenica

Excellence in Single Domain Biotherapeutics

Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.

LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.

Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.

Partnerships

Isogenica Biopharmaceutical Partnerships

Accelerated Discovery

Isogenica’s LlamdA® VHH synthetic libraries are displayed in phage or in the company’s proprietary CIS Display technology.

These are combined to provide a powerful discovery engine for single domain biotherapeutics.

News & Events

Isogenica supports MRC iCASE PhD Award

The successful applicant will gain industry experience in single domain VHH antibody discovery at Isogenica and characterisation at renowned haematology research labs of Professor Martin Dyer, University of Leicester

Careers at Isogenica

A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.